What this means
This trial plans to study whether shock may age certain cells, which could raise later heart and infection risk. It has not reported results, so it does not yet show whether this happens.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 1 site
The science
- Registered title
- Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States
- Trial ID
- NCT03559569 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Shock, Cardiovascular Diseases, Infection
- What is tested
- Biological samples will be done to evaluate the endothelial and leukocyte senescence.
- Sponsor
- University Hospital, Strasbourg, France
- Ages
- 18 Years to no maximum
- Dates
- First posted Jun 18, 2018 · updated Mar 10, 2025
Registry summary
Circulatory shocks (CS) are life-threatening, acute organ dysfunction. Advances in critical care medicine have decreased early hospital mortality, increasing the number of surviving patients. Regrettably, these survivors are at increased risk of new infections but also of cardiovascular disease.
The investigators hypothesize that CS with multi-organ dysfunction is associated with premature senescence of endothelial cells and immune cells and promotes endothelial thrombogenicity and immunosenescence leading to cardiovascular disease and secondary infections.
The aim of this work is therefore to evaluate the contribution of endothelial and leucocytes senescence to the occurrence of secondary events (infectious and cardiovascular) in patients with a CS. It will provide a better understanding of the pathogenesis of cardiovascular and immune diseases following a CS, likely to guide new management strategies to prevent their occurrence.
Sites (1)
- Hôpitaux Universitaires de Strasbourg - Service de Réanimation médicale du NHC, Strasbourg, France